The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.75
Bid: 31.50
Ask: 32.00
Change: -0.25 (-0.78%)
Spread: 0.50 (1.587%)
Open: 31.75
High: 31.75
Low: 31.75
Prev. Close: 32.00
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of the Fundraising and Notice of EGM

5 Dec 2017 15:18

RNS Number : 4657Y
Duke Royalty Limited
05 December 2017
 

 

Duke Royalty Limited

("Duke Royalty" or the "Company")

 

Result of the Fundraising and Notice of EGM

 

Further to the announcement released by the Company dated 4 December 2017 (the "Fundraising Announcement"), the Company is pleased to announce that it has successfully raised £20.0 million before expenses and will, subject to Shareholder approval as noted below, apply for its shares to be admitted to AIM with admission expected to take place at 8.00 a.m. on or around 22 December 2017.

DEFINITIONS

 

Other than where defined, capitalised terms used in this announcement have the meanings given to them in the Fundraising Announcement.

 

Result of Fundraising

Pursuant to the Fundraising Announcement, the Company is pleased to announce that a total of  50,000,000 New Shares have been successfully placed or subscribed for in the Company at a price of 40 pence per New Share, with new and existing institutional investors, as well as certain Directors. Pursuant to the Fundraising, the Company has raised gross proceeds of £20.0 million (net proceeds of approximately £18.8 million after expenses).

Cenkos Securities plc and Mirabaud Securities Limited acted as joint bookrunners in connection with the Placing. Grant Thornton acted as nominated adviser to the Company.

Notice of Extraordinary General Meeting ("EGM")

The Fundraising is conditional on Shareholders passing a resolution authorising the Directors to allot the New Shares as if the rights of pre-emption in Article 4.2 of the Articles of the Company did not apply to any such issue. An extraordinary resolution is passed where no less than 75 per cent. of those present and entitled to vote, or voting by proxy, in a general meeting vote in favour for it to be passed.

The EGM of the Company is to be held at 10:00 a.m. on 21 December 2017 at the offices of Trident Trust 4th Floor, West Wing, Trafalgar Court, Admiral Park, St Peter Port, Guernsey, GY1 2JA.

A copy of the circular and Notice of EGM will be posted to Shareholders today and will shortly be available on the Company's website at www.dukeroyalty.com.

Recommendation

The Directors recommend that Shareholders should vote in favour of the Resolution, as they intend to do in respect of their combined holdings of 6,075,000 Existing Ordinary Shares, representing 13.39 per cent. of the issued share capital of the Company.

Expected Timetable of Principal Events

Announcement of the result of the Fundraising and Notice of EGM

5 December 2017

Circular and Form of Proxy published

5 December 2017

Latest date and time for receipt of proxy forms

10:00 a.m.

19 December 2017

Extraordinary General Meeting

10:00 a.m.

21 December 2017

Announcement of the results of the Extraordinary General Meeting

10:00 a.m.

21 December 2017

Admission and commencement of dealings in New Shares

8.00 a.m.

22 December 2017

New Shares in uncertificated form expected to be credited to accounts in CREST

As soon as possible after 8.00 a.m.

22 December 2017

Despatch of definitive share certificates for the New Shares in certificated form

Within 10 business days of Admission

 

Share issue pursuant to Support Services Agreement

As previously announced by the Company, under the terms of the Support Services Agreement dated 16 June 2015 made between the Company and Abingdon Capital Corporation ("Abingdon"), 1,500,000 new Ordinary Shares ("Incentive Shares") are to be issued following the successful completion of the first and second royalty debt instruments of the Company and in satisfaction of all Incentive Share obligations. Following the royalty arrangements, as announced on 6 April 2017 and 6 October 2017, the Company will issue these 1,500,000 shares as directed by Abingdon, being 1,070,193 to Abingdon and 429,807 to Arlington Group Asset Management Limited ("Arlington").

Total Voting Rights

Pursuant to the Fundraising, application will be made for the admission of the New Shares, and pursuant to the Support Services Agreement, the Incentive Shares, to trading on AIM ("Admission"). Subject to the Placing Agreement not having been terminated in accordance with its terms and the passing of the Resolution at the EGM of the Company, it is anticipated that Admission will occur at 8.00 a.m. on 22 December 2017. The New Shares and the Incentive Shares will be credited as fully paid and rank pari passu with the Existing Ordinary Shares.

Following Admission, the Company will have a total of 96,877,459 Ordinary Shares in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Directors' shareholdings

The following Directors participated in the Fundraising as follows:

Name

No. of Existing Ordinary Shares

No. of New Shares

Incentive Shares to be issued to Abingdon / Arlington

Total holding

Percentage ofenlarged issuedshare capitalfollowingAdmission

Neil Johnson (1)

1,760,000

252,000

1,070,193

3,082,193

3.2

Charles Cannon-Brookes (2)

3,100,000

998,000

429,807

4,527,807

4.7

 

 (1) Of these, currently 500,000 are legally owned by Abingdon. Mr Johnson is Abingdon's sole voting shareholder. Following the issue of Incentive Shares, Abingdon will legally own 1,570,193 Ordinary Shares on Admission.

(2) Of this holding, prior to the Fundraising 1,500,000 Ordinary Shares are legally owned by Arlington and Arlington has subscribed for 525,000 New Shares, representing £210,000 in the Fundraising. Mr Cannon-Brookes is the investment director of Arlington and holds 40 per cent. of the voting shares of Arlington. Mr Cannon-Brookes has subscribed in his own name for 473,000 New Shares, representing £189,200, in the Fundraising. Following the issue of Incentive Shares, Arlington will legally own 2,454,807 Ordinary Shares on Admission.

Related Party Transactions

The participation in the Fundraising by the Directors and their associates, set out in the above table, is deemed to be a related party transaction pursuant to the AIM Rules. In addition, Hargreave Hale Limited, a substantial shareholder in the Company, has agreed to subscribe for 8,265,000 shares in the Fundraising which also falls to be treated as a related party transaction under the AIM Rules.

The directors independent of the participation in the Fundraising (being the directors excluding Charlie Cannon Brookes and Neil Johnson), consider, having consulted with the Company's nominated adviser, Grant Thornton, that the terms of the Directors' and their associates' participation in the Fundraising are fair and reasonable insofar as the Company's Shareholders are concerned. The directors consider, having consulted with the Company's nominated adviser, Grant Thornton, the participation of Hargreave Hale Limited in the Fundraising to be fair and reasonable insofar as the Company's Shareholders are concerned.

For further information, please contact:

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon-Brookes

+44 (0) 1481 741 240

Grant Thornton UK LLP (Nominated Adviser)

Colin Aaronson / Samantha Harrison / Carolyn Sansom

+44 (0) 20 7383 5100

Cenkos Securities plc (Joint Broker)

Julian Morse / Michael Johnson

+44 (0) 207 397 8900

Mirabaud Securities Limited (Joint Broker)

Peter Krens / Edward Haig-Thomas

+44 (0) 20 3167 7222

 

 

Prior to publication, certain information contained within this Announcement was deemed to constitute inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 ("MAR"). In addition, certain market soundings (as defined in MAR) were taken in respect of the Fundraising with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. As a result of the publication of this Announcement, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities.

 

About Duke Royalty

Headquartered in Guernsey, Duke Royalty Limited provides alternative financing solutions to a diversified range of businesses in Europe and abroad. Duke Royalty's experienced team and exclusive partnership provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its Shareholders.

Duke Royalty is listed on the AIM market under the ticker DUKE. For more information, visit www.dukeroyalty.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOGFSMFIIFWSEFE
Date   Source Headline
3rd May 20247:00 amRNSFollow-On Investment into Existing Capital Partner
29th Apr 20242:45 pmEQSHardman & Co Research Initiation of Coverage on Duke Capital (DUKE): Meeting customer needs, giving investors returns
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat
6th Mar 20247:00 amRNSSuccessful Exit of Investment
4th Mar 20247:00 amRNSIncreased Equity Stake in United Glass Group
21st Feb 202411:57 amRNSName Change Effective
20th Feb 202412:08 pmRNSResult of General Meeting & Change of Name
5th Feb 20247:00 amRNSProposed Change of Name, Website and Messaging
29th Dec 20237:00 amRNSTrading Update and Follow-on Investment
19th Dec 20237:00 amRNSInterim Dividend and Dividend Declaration
29th Nov 20237:00 amRNSUpdate re. Change of Name of Nominated Adviser
22nd Nov 20237:00 amRNSFinancial Year 2024 Interim Results
21st Sep 20237:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20237:00 amRNSTrading Update
2nd Aug 20234:51 pmRNSResult of Annual General Meeting
31st Jul 20237:00 amRNSNew Royalty Agreement
28th Jul 20237:00 amRNSDirector/PDMR Dealings
20th Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
4th Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
3rd Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
26th Jun 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
15th Jun 20237:00 amRNSInterim Dividend and Dividend Declaration
9th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSTrading Update
25th May 20237:00 amRNSDirectors' Dealings
24th May 20237:00 amRNSSuccessful Exit of Investment in Royalty Partner
22nd Mar 20237:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20237:00 amRNSNew Royalty Agreement
3rd Mar 20237:00 amRNSTrading Update
21st Feb 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
16th Jan 20237:00 amRNSClosing of New Credit Facility
15th Dec 20223:35 pmRNSInterim Dividend and Dividend Declaration
13th Dec 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
12th Dec 20227:00 amRNSRefinance and Upsize of Credit Facility
1st Dec 20227:01 amRNSTrading Update
1st Dec 20227:00 amRNS2023 Interim Results
29th Nov 202212:38 pmRNSResult of Annual General Meeting
25th Nov 20227:00 amRNSNew Royalty Agreement
14th Nov 20227:00 amRNSNotice of AGM and Notice of Interim Results
14th Oct 20227:00 amRNSPSAs, Issue of Equity & Director/PDMR Dealings
22nd Sep 20227:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20229:09 amRNSPublication of Annual Report & Accounts
9th Sep 20227:00 amRNSPostponement of Presentation
8th Sep 20227:00 amRNSFinal Results for the year ended 31 March 2022
31st Aug 20225:04 pmRNSHolding(s) in Company
30th Aug 20223:07 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.